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Background: COPD is a heterogeneous disease comprising a wide range of clinical
phenotypes, depending on the degree to which emphysema, chronic bronchitis, reversible
bronchospasm and small airways inflammation are present. Not all of these phenotypes
may be represented among the subjects included in randomized controlled drug trials
(RCTs) in COPD, making it difficult for doctors to know to what extent RCTevidence applies
to individual patients. From a respiratory health survey of adults randomly selected from
the community, we have estimated the proportion of subjects with COPD who would have
been eligible for inclusion in major COPD RCTs.
Methods: A postal survey was sent to 3500 randomly selected individuals aged 25–75
years. Respondents were invited to complete a detailed respiratory questionnaire and
pulmonary function tests. Subjects with COPD defined by post-bronchodilator spirometry
were assessed against the eligibility criteria of 18 major RCTs cited in the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidelines.
Findings: Of 749 subjects completing the full survey, 117 had COPD. Of these, a median of
5% (range 0–20%) of subjects met inclusion criteria for the major RCTs. Of 55 subjects with
COPD receiving treatment, 0–9% (median 5%) met inclusion criteria for the major RCTs.
Interpretation: The major COPD RCTs on which the GOLD treatment guidelines are based
may have limited external validity. Over 90% of the COPD subjects in the community who were
taking medication, did so on the basis of RCTs for which they would not have been eligible.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
arch Institute of New Zealand, PO Box 10055, Wellington, New Zealand. Tel.: +64 4 4729199;
rinz.ac.nz (R. Beasley).
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J. Travers et al.1314Introduction
In the past, a doctor’s personal clinical experience often
formed the basis of therapeutic decision-making. However,
doctors have increasingly recognised the importance of the
clinical evidence derived from randomized controlled trials
(RCTs) and presented in evidence-based treatment guide-
lines, considered alongside clinical experience. Ideally these
RCTs would be relevant and generalisable to the full spectra
of patients and the complex variety of complaints with
which they present to doctors in everyday clinical practice.
This requires research to be well designed with clinically
relevant outcome measures, to have a high degree of
external validity, and be based on ‘‘real-life clinical’’ rather
than ‘‘controlled’’ conditions.1 However, many RCTs that
inform treatment guidelines have restricted subject selec-
tion criteria and are performed under conditions that are
not easily replicated in clinical practice.1 Practical con-
siderations and a desire for high internal validity often
encourage subject selection to be restricted to those most
likely to respond to the intervention, patients with the most
typical features of a disease, or those most available to
participate in research. While in the early stages of assessing
novel treatments, it is preferable to undertake efficacy
studies under such controlled conditions, such studies alone
are insufficient to determine the treatment recommenda-
tions in guidelines. Efficacy studies should be followed by
effectiveness studies, which test whether a new treatment
provides benefit in real-life clinical settings.2
COPD presents a particular challenge as it is a hetero-
geneous disease with a wide range of phenotypes among
individuals depending on the degree to which emphysema,
chronic bronchitis, asthma and small airways inflammationPostal questionnaires mailed out. 
N=3500 
Responded to postal questionnaire. 
N=2319 
Completed detailed questionnaire. 
N=1017 
Completed pulmonary function testing, 
Included in study group. 
N=749 
Figure 1 Flow diagram for the Wmay be present.3 Other variables such as the degree of
dyspnea, concomitant disorders and complications such as
respiratory failure and cor pulmonale further contribute to
the diversity of this disease. Despite this, measurement of
the efficacy of COPD treatments across a range of different
COPD phenotypes is not usually undertaken, resulting in
uncertainty regarding the generalisability of the results to
patients with COPD.
We have recently shown that the major asthma RCTs on
which the GINA guidelines4 are based have limited external
validity, as they have been performed on highly selected
patient populations.5 Indeed, almost all of the subjects with
current asthma on treatment in the community would not
have been eligible for these RCTs. We now extend these
observations in our community-based survey of respiratory
health to determine the proportion of individuals with COPD
who would have met the eligibility criteria for the RCTs
forming the basis of the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines.6Methods
Subjects
Study participants in the Wellington Respiratory Survey
(WRS) which was carried out between 2002 and 2005 in
Wellington, New Zealand, were recruited using a postal
questionnaire sent to 3,500 individuals aged 25–75 years,
randomly selected from the electoral register (Fig. 1).7 The
2319 subjects who responded to the postal questionnaire
were invited to undertake the full survey which included a
detailed, interviewer administered questionnaire, pulmon-Did not respond. N=659 
Invalid address. N=509 
Deceased. N=13 
Declined further participation. N=868 
No co ntact details provided. N=434 
Declined further participation. N=222 
Unable to complete satisfactory 
pulmonary function testing. N=46 
ellington respiratory survey.
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External validity of COPD trials 1315ary function tests, skin prick tests to common allergens, and
a one week peak flow diary.
Pulmonary function testing
Pulmonary function tests carried out in the WRS have been
described previously.7 In brief, these were carried out using
two Jaeger Master Screen Body heated pneumotachographs
(Masterlab 4.5 and 4.6, Erich-Jaeger, Wurzberg, Germany)
according to ATS guidelines.8 Spirometry was carried out
before and after the administration of 400 mg of salbutamol
inhaled via a spacer device. Subjects were not tested within
3 weeks of an upper or lower respiratory tract infection. The
survey was approved by the Wellington Ethics Committee
and written informed consent was obtained from each
subject.
Identification of subjects with COPD
Subjects were identified as having COPD if the post-
bronchodilator ratio of forced expiratory volume in 1 s
(FEV1) to forced vital capacity (FVC) was o0.7 in the
absence of specific pulmonary pathology such as bronchiec-
tasis or tuberculosis.6 Subjects with COPD who were taking
inhaled or oral steroids, or bronchodilators were identified
as having COPD on treatment.
Identification of RCTs
We sought to identify RCTs that impact on the pharmaco-
logic management of COPD worldwide. We examined the
trials cited in the GOLD consensus guidelines as these
guidelines have a worldwide influence (Fig. 2). We used the
following prespecified conditions to identify the key RCTs. Cited in the GOLD guidelines, 2005 update, chapter 5
‘‘Management of COPD’’, component 3 ‘‘Manage stable
COPD’’, section ‘‘Pharmacologic treatment’’.6 Citation relates to a treatment recommendation.
 Treatment recommendation is evidence-graded as grade
A or B.
 Citation of a RCT evaluating pharmacologic therapy in
adults with COPD.
 RCT with at least 400 subjects randomized.
 RCT published in the last 30 years.
RCTs were identified in a systematic manner.9 Where a
systematic review or meta-analysis was cited, the trials
included in the review or meta-analysis were also screened
for inclusion. References were assessed independently by
two reviewers (JT, BC). Inclusion and exclusion criteria were
obtained from the full text of all qualifying trials.
Analysis
The proportion of subjects with COPD who met the eligibility
criteria for each of the identified RCTs was determined.
Where we were unable to determine from our survey data
whether a subject met a particular eligibility criterion, the
subject was considered to meet that criterion. For example,a RCT may have the criterion that subjects be exacerbation
free in the previous two months whereas our survey
recorded only that subjects were exacerbation free in the
preceding three weeks. In this case, all subjects who were
exacerbation free for 3 weeks were considered to meet this
criterion and remain potentially eligible.
The WRS study sponsor had no involvement in the study
design, collection, analysis or interpretation of data, the
writing of this report or the decision to submit for
publication.Results
Of the 2319 subjects who responded to the postal survey,
749 subjects completed the detailed questionnaire and
satisfactory pulmonary function testing and form the study
group (Fig. 1). Of these 749 subjects, 117 (16%) met the
spirometry-based criteria for COPD and 55 (7%) met the
criteria for COPD on treatment. The characteristics of these
subjects are presented in Table 1.
Compared to the 1570 survey respondents who were not
included in the study group, the study group had a higher
rate of physician diagnosed asthma (23.1% vs. 17.3%), were
more likely to be male (53.7% vs. 44.3%) and ex-smokers
(41.4% vs. 35.3%). There were no significant differences in
the prevalence of physician diagnosed chronic bronchitis or
emphysema.
There were 109 individual references in the relevant
section of the GOLD guidelines from which 18 qualifying
RCTs were identified and included in the analysis
(Fig. 2).10–27 The characteristics of the included RCTs are
given in Table 2. Inclusion criteria used in all 18 RCTs were: a
specified FEV1 range and greater than a specified amount of
smoking. Seventeen RCTs required objective evidence of
airflow obstruction; in 14 trials this was defined as a ratio of
FEV1 to FVC of o0.7. A total of 17 RCTs specified an age
range, 11 specified the requirement for a physician diagnosis
of COPD, and 9 required symptoms of COPD. Eight RCTs
required limited reversibility of airflow obstruction after a
bronchodilator, five required subjects to be previously
taking specified medication and four had other inclusion
criteria. The most common exclusion criteria were poten-
tially confounding medication use in 17 RCTs and asthma or
atopy, variously defined, in 16 RCTs. Other exclusion criteria
were recent COPD exacerbation in 13 RCTs, long-term
oxygen therapy in 11, other systemic disease in 11, other
pulmonary disease in 7 and other exclusion criteria in two
RCTs.
The proportion of subjects with COPD in the WRS who met
the eligibility criteria for these 18 RCTs ranged from 0% to
20% with a median of 5% (Table 3). The proportion of
subjects with COPD on treatment who met the eligibility
criteria for these trials ranged from 0% to 9% with a median
of 5% (Table 3).
Table 4 shows the proportion of subjects with COPD from
the WRS who would be omitted from RCTs on the basis of
commonly used exclusion criteria. The most restrictive
criterion was the requirement for a physician diagnosis of
COPD which excluded 86% of our subjects with COPD. The
requirements to have smoked at least 10 pack-years of
ARTICLE IN PRESS
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12 references 
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(3 re-analyses of included RCTs, 2 published 
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Figure 2 Flow diagram for selection of RCTs from the global strategy for the diagnosis, management and prevention of chronic
obstructive pulmonary disease.6
J. Travers et al.1316cigarettes and to be non-atopic would each have excluded
about half of our COPD subjects.Discussion
This study demonstrates that only about one in 20 people
with COPD identified from a large general population survey
would have met the inclusion criteria for the major
randomized controlled trials informing consensus guidelines
in COPD. As a result, there is uncertainty about how
applicable the results of these studies are to the vast
majority of COPD patients.
We have shown that the restrictive inclusion criteria of
the RCTs included in this study potentially resulted in
considerable selection bias when compared to those withCOPD from the general population. For example, the
common requirement for a doctor’s diagnosis of COPD
excluded six out of every seven people with COPD in our
community sample. Most of the RCTs informing COPD
treatment guidelines excluded people with asthma. This
criterion markedly reduces the number of COPD subjects
with the potential for bronchodilator reversibility and thus
reduces the chance of finding an improvement with inhaled
corticosteroid or bronchodilator treatment. Similarly, the
common requirement for COPD subjects to be ex or current
smokers may self-select a subgroup with a poor response to
inhaled corticosteroid therapy.28,29 Such factors may partly
explain the recently challenged nihilistic attitude towards
COPD treatment.30
Not only do the restrictive inclusion-exclusion criteria of
the major RCTs give limited guidance to clinical decision
ARTICLE IN PRESS
Table 1 Characteristics of subjects with COPD and with
COPD on treatment.
COPD COPD on
treatment
N ¼ 117 N ¼ 55
Mean (SD) Mean (SD)
Age (years) 62.6 (10.6) 61.3 (11.0)
FEV1 pre-bronchodilator,
per cent of predicted (%)
68.8 (19.6) 58.5 (19.5)
FEV1 post-
bronchodilator, per cent
of predicted (%)
75.1 (19.0) 66.1 (19.6)
N (%) N (%)
Female sex 36 (31) 20 (36)
Smoker 55 (47) 21 (38)
Doctor’s diagnosis of
asthma
47 (40) 44 (80)
Doctor’s diagnosis of
COPD, chronic bronchitis
or emphysema
17 (15) 15 (27)
Exacerbation in
preceding 12 months y
17 (15) 17 (31)
Dyspnea 73 (62) 52 (95)
Any COPD medication
use in the previous 12
monthsz
55 (47) 55 (100)
Inhaled corticosteroid
use in the previous 12
months
39 (33) 39 (71)
Inhaled short acting beta
agonist use in the
previous 12 months
48 (41) 48 (87)
Disease severity
GOLDz stage 1 54 (46) 15 (27)
GOLD stage 2 52 (44) 29 (53)
GOLD stage 3 8 (7) 8 (15)
GOLD stage 4 3 (3) 3 (5)
Significant
bronchodilator
reversibilityy
35 (30) 23 (42)
FEV1: forced expiratory volume in 1 s.
Current or ex smoker with more than 10 pack-years
cigarette smoke exposure.
yOral steroid use or hospital attendance in previous 12
months.
zOral or inhaled corticosteroids, short or long-acting
inhaled bronchodilators.
zGlobal initiative for chronic obstructive lung disease.6
yX12% plus X200ml increase in FEV1 following broncho-
dilator.
External validity of COPD trials 1317making, these criteria also limit knowledge of COPD since
studies restricted by these criteria cast no light on the
complexity of the clinical phenotype of COPD. COPD
comprises a range of clinical entities and physical manifes-
tations and it is not entirely clear to what extent these
phenotypes influence the response to different treatmentapproaches.31 Extension of clinical trials to include different
phenotypic variants of COPD could therefore provide
information on the nature of these phenotypes and how
they influence the response to treatment.
We suggest that future RCT designs should not necessarily
exclude subjects who are non-smokers, demonstrate
bronchodilator reversibility or have a concomitant diagnosis
of asthma. The inclusion of non-smokers may be particularly
important in developing countries, in which exposure to
indoor air pollution is an important cause of COPD,
predominantly in women.32 More generally, it is now
recognised that only about half of all cases of COPD may
be attributed to tobacco smoking.33 The inclusion of
subjects with concomitant asthma would recognise the
importance of asthma as a major risk factor for the
subsequent development of COPD.34 Although including a
wider range of COPD subjects in future RCTs may increase
complexity and may necessitate the enrolment of larger
numbers of subjects, these practical difficulties are offset
by improved recruitment rates and the ability to determine
therapeutic responses in different phenotypic subgroups.
A potential limitation which was not addressed in our
study is the influence of the standard procedure of assessing
a subject’s eligibility for a COPD trial on only one occasion.
There is evidence that major differences in classification
may occur as a result of repeat assessment of bronchodilator
reversibility due to the intrinsic variability of this measure-
ment in subjects with COPD.35 Another consideration is the
role of other measurements such as HRCT scanning and
parameters of airways and systemic inflammation.36–39 With
a greater understanding of the relevance of these measures
to different COPD phenotypes it is likely that they will need
to be incorporated in eligibility criteria.
There were several methodological issues relevant to the
present analysis. The study group was selected at random
from the community yet may not be fully representative of
the target population. The characteristics of individuals
with an invalid address and of non-respondents to the postal
questionnaire may have been different to the study group
resulting in a non-response bias. The characteristics of the
study group were broadly similar to those of postal
questionnaire respondents who did not complete all
investigations however there were slightly more subjects
with asthma, male subjects and ex-smokers in the study
group. The effect of these differences on our findings is not
clear; however, the higher rate of asthma in the study group
may have resulted in a slight overestimation of the true
degree of selectivity of these RCTs.
Rather than perform an exhaustive systematic review of
all randomized clinical trials in COPD, we instead focussed
on those trials that had the most influence on clinicians’
treatment decisions, namely those RCTs that form the basis
for the most recent GOLD consensus treatment guidelines.6
The condition that an included RCT randomized at least 400
subjects was chosen so that all included RCTs could be
considered to be large trials. It is possible that there are
important published RCTs that were not used in the
formation of the GOLD guidelines or that did not meet our
conditions for inclusion but which may be more representa-
tive of the variety of COPD patients and their phenotypes in
the community. However, the RCTs analysed here all
demonstrate a high degree of selectivity suggesting that a
ARTICLE IN PRESS
Table 2 Characteristics of included RCTs.
Reference Number of subjects
randomized
FEV1 range
 (mean
FEV1 of randomized
subjects)
Age range in
years
Interventions
10 534 o65 (37) 40+ Albuterol/ipratropium vs.
albuterol vs. ipratropium
11 5887 55–90 (75) 35–60 Smoking cessation intervention/
ipratropium vs. smoking
cessation intervention/placebo
vs. usual care
12 652 p65 (34) 40+ Albuterol/ipratropium vs.
albuterol vs. ipratropium
13 674 o70y 40–75 Salmeterol (two different doses)
vs. placebo
14 863 25–65y 40+ Albuterol/ipratropium vs.
abuterol vs. ipratropium
15 411 p65 (40) 35+ Salmeterol vs. ipratropium vs.
placebo
16 1277 50–100z (77) 30–65 Budesonide vs. placebo
17 1116 30–90 (64) 40–69 Triamcinolone vs. placebo
18 751 o85 (50) 40–75 Fluticasone vs. placebo
19 780 o70 (45) 40+ Formoterol vs. ipratropium vs.
placebo
20 921 p65 (39) 40+ Tiotropium vs. placebo
21 691 o65 (41) 40+ Salmeterol/fluticasone vs.
salmeterol vs. fluticasone vs.
placebo
22 854 o70 (47) 40+ Formoterol vs. placebo and
theophylline vs. placebo
23 535 o65 (41) 40+ Tiotropium vs. ipratropium
24 1465 25–70 (45) all ages Salmeterol/fluticasone vs.
salmeterol vs. fluticasone vs.
placebo
25 1022 p50 (36) 40+ Formoterol/budesonide vs.
formoterol vs. budesonide vs.
placebo
26 723 o65 (42) 40+ Salmeterol/fluticasone vs.
salmeterol vs. fluticasone vs.
placebo
27 812 p50 (36) 40+ Formoterol/budesonide vs.
formoterol vs. budesonide vs.
placebo
FEV1: forced expiratory volume in 1 s.
Pre-bronchodilator FEV1 expressed as per cent of predicted.
yMean FEV1 as per cent of predicted not reported. Mean absolute FEV1 was 1.28 and 1.15 L for Refs. [13,14], respectively.
zFEV1 range refers to post-bronchodilator values.
J. Travers et al.1318similar analysis of other trials is likely to yield similar
results. In order to obtain a realistic estimate of the degree
of selectivity of existing COPD trials we examined RCTs that
have been performed and published rather than a hypothe-
tical ‘typical’ RCT.40
We were not always able to determine from our survey
data whether a subject with COPD met a particular criterion
of an RCT or not as many trials used criteria for exacerba-
tions, symptom scores and measures of medication use
which we were not able to duplicate. Where this occurred,
subjects were deemed to remain eligible by the criterion wecould not assess. Hence, our estimates of the proportion of
subjects with COPD eligible for a given trial are maximum
values and the true degree of selectivity of these RCTs may
be greater than we have shown.
We conclude that a significant number of people in the
community with diagnosed and undiagnosed COPD would not
meet selection criteria for inclusion as subjects in the RCTs
that inform consensus treatment guidelines. The degree to
which RCT findings apply to individuals cannot be easily
quantified and the doctor cannot assume that his or her
patient will respond to a medication in the same way as trial
ARTICLE IN PRESS
Table 3 Individuals from the WRS meeting eligibility
criteria for COPD RCTs.
Reference Year COPD (%) COPD on
treatment (%)
N ¼ 117 N ¼ 55
10 1994 A_MRK2A_MRK4
11 1994 5 0
12 1997 1 2
13 1997 6 9
14 1998 3 7
15 1999 9 9
16 1999 8 0
17 2000 10 0
18 2000 20 7
19 2001 16 9
20 2002 5 5
21 2002 3 4
22 2002 16 9
23 2002 4 5
24 2003 0 0
25 2003 2 4
26 2003 3 4
27 2003 3 7
WRS: Wellington respiratory survey.
Table 4 Selectivity of eligibility criteria.
Criterion Percentage of WRS
subjects with COPD
excluded by criterion (%)
Doctor’s diagnosis
compatible with COPD
86
No atopy 57
FEV1 X 50% and o80% of
predicted
57
At least 10 pack-years
cigarette exposure
55
No asthma diagnosis 42
Bronchodilator
reversibility o15%
29
Age at least 40 years 9
WRS: Wellington respiratory survey.
COPD: chronic obstructive pulmonary disease.
FEV1: forced expiratory volume in 1 s.
Positive skin prick test to a common allergen.
External validity of COPD trials 1319subjects do. The RCT evidence, appropriately weighted for
applicability, should be considered alongside clinical experi-
ence and patient preference among other factors when
making treatment decisions for individuals with COPD. We
recommend that RCTs in COPD include a wider range of
subjects such as non-smokers and those with a concomitant
asthma phenotype, to ensure greater generalisability of the
findings to clinical medicine.
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